Visterra Inc.
We bring better biologics to life. Biospace Best Place to Work 2024!
Waltham, United States
139 employees
Series C
Total: $125.39M
Biotechnology, Health Care +1
General Information
Get notified when Visterra Inc. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Visterra Inc.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About Visterra Inc.
Taxonomy: biologics, biotechnology company, antibody-based therapies, precision medicine, kidney diseases, clinical stage, novel therapies, unmet medical needs, Phase 2 clinical development, partnerships, engineering precision antibodies, disease targets, innovative treatments, drug development, biomedical research
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | •••••• | 10 |
|
05 Oct 2017 |
| Series C | •••••• | 6 |
|
01 Jun 2016 |
| Series B | •••••• | 10 |
|
02 Oct 2014 |
| Series A | •••••• | 5 |
|
02 Dec 2013 |
| Series A | •••••• | 5 |
|
09 Nov 2012 |
Visterra Inc. Alternatives & Competitors
Harnessing the power of microglia to transform treatments for neurodegenerative diseases
Developing a new approach to combating Alzheimer's disease and other neurodegenerative diseases.
Advancing a new paradigm of precision oncology with a RNA-based approach to match patients to novel,...
FAQ About Visterra Inc.
Don't just browse. Track.
Signal Tracker monitors Visterra Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.